abca

Tanshindiol C protects macrophages from oxLDL induced foam cell formation via activation of Prdx1/ABCA1 signaling and that Prdx1 may be a novel target for therapeutic intervention of atherosclerosis.It possesses a unique anti-cancer activity whose mechani

ABCA1 inducer 1, a non-lipid inducer of ABCA1, enhances ABCA1 expression in E3/4FAD mice expressing human APOE 3/4, augments the lipidation of apolipoprotein (APOE), and reverses various Alzheimer's disease (AD) phenotypes without increasing triglycerides.

ABCA1 inducer 2 is a non-lipogenic inducer of ABCA1. It increases the expression of ABCA1 by targeting the LXR pathway, thereby reducing lipid accumulation induced by ox-LDL and inhibiting foam cell formation. ABCA1 inducer 2 holds potential as an anti-atherosclerotic agent.

ABCA1 inducer 3 (Compound 85) is an orally active ABCA1 inducer and lipid regulator. It enhances ABCA1 expression levels and upregulates mRNA expression of Abcg5 and Abcg8 in the liver. Additionally, ABCA1 inducer 3 promotes cholesterol efflux and ameliorates hyperlipidemia.

Probucol (DH-581), an anti-hyperlipidemic drug, can lower the level of cholesterol in the bloodstream by increasing the LDL catabolic rate.

MC-Val-Cit-PAB-carfilzomib is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADC), comprising the irreversible proteasome inhibitor carfilzomib, connected through the ADC linker MC-Val-Cit-PAB.

MC-VC-PABC-Aur0101 is a potent anticancer drug-linker conjugate for Antibody-Drug Conjugates (ADCs), incorporating Aur0101, an auristatin microtubule inhibitor, linked via the MC-VC-PABC linker to boost antitumor efficacy.

Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB carbonic acid is a PROTAC linker utilized in the synthesis of L1BC8.

GSK3987 is an LXR ligand. GSK3987 recruits the steroid receptor coactivator-1 to human LXRalpha and LXRbeta with EC50s of 40 nM.

MC-VC-PABC-amide-PEG1-CH2-CC-885 is an Antibody-Drug Conjugate (ADC) that employs a protein-degrading agent (protac molecular glue, etc.).

Campesterol ((24R)-5-Ergosten-3β-ol) is a plant sterol with cholesterol lowering and anticarcinogenic effects, it and other plant sterols often decrease LDL cholesterol levels overall. Campesterol has anti-inflammatory effect, it inhibits several pro-inflammatory and matrix degradation mediators typically involved in osteoarthritis- induced cartilage degradation, also sometimes used to treat some specific prostate conditions.

1. Pseudoprotodioscin has moderate cytotoxicity.

Erythrodiol, an olive oil component, promotes Cholesterol efflux (ChE) by selectively inhibiting the degradation of ABCA1 protein.

Val-Cit-PABC-Ahx-May TFA serves as a cleavable ADC linker in the production of antibody-drug conjugates (ADCs) [1].

Val-Cit-PABC-Ahx-May serves as a cleavable ADC linker in antibody-drug conjugate (ADC) synthesis [1].

OSBPL7-IN-1 is an orally active inhibitor of oxysterol binding protein like 7 (OSBPL7) that promotes an increase of ABCA1 at the plasma membrane without affecting mRNA expression[1].

Alemtuzumab is a humanized monoclonal antibody against CD52 an antigen found on the surface of normal and malignant lymphocytes.

Isosilybin A is a partial PPARγ agonist, it significantly induced ABCA1 protein expression, it inhibited both monophenolase (IC50=1.7-7.6μM) and diphenolase (IC50=12.1-44.9μM) of tyrosinase. Isosilybin A shows anti-angiogenic efficacy, it has anti-prostate cancer (PCA) activity that is mediated via cell cycle arrest and apoptosis induction.

CS-6253 is an agonist of ATP Binding Cassette 1 (ABCA 1). It modulates the amyloid beta Aβ42/40 ratio, influencing lipoprotein metabolism in the plasma. Additionally, CS-6253 promotes the production of cholesterol-rich high-density lipoprotein (HDL) particles and induces the release of microparticles.